Alnylam Pharmaceuticals/$ALNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Ticker
$ALNY
Sector
Primary listing
Employees
2,230
Headquarters
Website
ALNY Metrics
BasicAdvanced
$61B
-
-$2.46
0.22
-
Price and volume
Market cap
$61B
Beta
0.22
52-week high
$467.71
52-week low
$205.87
Average daily volume
1.2M
Financial strength
Current ratio
2.801
Quick ratio
2.633
Long term debt to equity
1,035.997
Total debt to equity
1,093.309
Interest coverage (TTM)
-1.18%
Profitability
EBITDA (TTM)
-123.687
Gross margin (TTM)
83.64%
Net profit margin (TTM)
-12.96%
Operating margin (TTM)
-7.32%
Effective tax rate (TTM)
15.94%
Revenue per employee (TTM)
$1,100,000
Management effectiveness
Return on assets (TTM)
-2.63%
Return on equity (TTM)
-257.82%
Valuation
Price to revenue (TTM)
24.595
Price to book
244.38
Price to tangible book (TTM)
244.38
Price to free cash flow (TTM)
-1,162.513
Free cash flow yield (TTM)
-0.09%
Free cash flow per share (TTM)
-0.402
Growth
Revenue change (TTM)
5.01%
Earnings per share change (TTM)
325.37%
3-year revenue growth (CAGR)
40.68%
10-year revenue growth (CAGR)
44.46%
3-year earnings per share growth (CAGR)
-32.94%
10-year earnings per share growth (CAGR)
0.47%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
ALNY News
AllArticlesVideos
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
Business Wire·2 weeks ago
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Benzinga·3 weeks ago
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
CNBC Television·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals (ALNY) has a market cap of $61B as of August 22, 2025.
What is the P/E ratio for Alnylam Pharmaceuticals stock?
The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of August 22, 2025.
Does Alnylam Pharmaceuticals stock pay dividends?
No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Alnylam Pharmaceuticals dividend payment date?
Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.